newsfilter
← Latest News
Business Wire·

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the